Influence of treatment on the maturation of the somesthetic pathway in infants with primary congenital hypothyroidism during the first year of life.
To assess the influence of treatment on the development of the somesthetic pathway in infants with congenital hypothyroidism receiving early treatment, median nerve somatosensory evoked potentials were measured during the 1st y of life. Twenty-nine infants were studied with six to seven somatosensory evoked potential tests per infant. The cervical latency (N13) divided by arm length and the first (N19) and second (N32) cephalic latencies as well as N13-N32 latency were measured. At diagnosis, all components showed a small but significant delay, which was not related to thyroxine (T4) levels before treatment. During treatment, T4 ranged from 50 to 290 nmol/L. At 12 mo, the cervical latency divided by arm length had normalized, whereas N19 and N13-N32 were more abnormal than at diagnosis. For N19, these abnormalities were related to a slow initial rise of T4 (< or = 100 nmol/L after 1 wk of treatment) and the initial N19 values. Abnormal N13-N32 values were associated with high T4 values during treatment (> 200 nmol/L) and the type of congenital hypothyroidism (partial or total deficiency in T4 production). Induction of therapy with l-triiodothyronine rather than l-thyroxine and the occurrence of low T4 values (< 100 nmol/L) after the 4th wk of therapy had no such effect. Our data suggest that, for normal CNS development, euthyroidism should be reached as soon as possible by adequate induction therapy. Thereafter, T4 supplementation should be strictly dosed, keeping the serum T4 values within narrow limits around the mean normal for age, because overtreatment, like initial undertreatment, may lead to CNS abnormalities at the end of the first year.
Bongers-Schokking
J J
JJ
Department of Pediatrics, Zuiderziekenhuis, Rotterdam, The Netherlands.
Colon
E J
EJ
Mulder
P G
PG
Hoogland
R A
RA
de Groot
C J
CJ
Van den Brande
J L
JL
D002490:Central Nervous System / Q000254:growth & development* / Q000503:physiopathology; D003409:Congenital Hypothyroidism; D005073:Evoked Potentials, Somatosensory; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000188:drug therapy* / Q000503:physiopathology; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood / Q000627:therapeutic use; D014284:Triiodothyronine / Q000627:therapeutic use
D014284:Triiodothyronine; D013972:Thyrotropin; D013974:Thyroxine